Results 31 to 40 of about 827 (180)

Carbapenem‐Resistant Acinetobacter baumannii Bloodstream Infection in a Ghanaian Patient with Unilateral Diaphragmatic Eventration and HIV Type 1 Infection

Case Reports in Infectious Diseases, Volume 2023, Issue 1, 2023., 2023
Carbapenem‐resistant Acinetobacter baumannii infection is a critically prioritized pathogen by the World Health Organization and a cause for growing concern due to increased mortality among hospitalised patients. Phrenic nerve palsy is a rare complication of herpes zoster infection of the C3, C4, and C5 nerve roots.
Yvonne Ayerki Nartey, Augustine Boakye Donkor, Ampem Darko Jnr Siaw, Oluwayemisi Esther Ekor, Bashiru Babatunde Jimah, Dawei Cui   +5 more
wiley   +1 more source

Population pharmacokinetic analyses for sulbactam-durlobactam using Phase 1, 2, and 3 data. [PDF]

Antimicrob Agents Chemother
ABSTRACT Sulbactam–durlobactam is a β-lactam/β-lactamase inhibitor combination approved in the United States for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii–calcoaceticus in adults.
Cammarata AP, Safir MC, Trang M, Larson KB, O'Donnell JP, Bhavnani SM, Rubino CM.   +6 more
europepmc   +3 more sources

Successful Treatment of OXA-23 <i>Acinetobacter baumannii</i> Pneumonia with Sulbactam-Durlobactam in a Liver Transplant Recipient. [PDF]

Infect Drug Resist
Liver transplant recipients face a higher risk of multidrug-resistant (MDR) infections because of preoperative comorbidities, extensive antibiotic use, immunosuppressive therapy, and prolonged mechanical ventilation. Carbapenem-resistant Acinetobacter baumannii (CRAB) remains one of the most challenging pathogens in this group.
Yin G, Liu Z, Fu Z, Zhong Z, Ye S, Pan H.   +5 more
europepmc   +3 more sources

The rising dominance of microbiology: what to expect in the next 15 years?

Microbial Biotechnology, Volume 15, Issue 1, Page 110-128, January 2022., 2022
Microbial research could lead to the development of in‐situ and ex‐situ rapid microbial detection systems based on microbial dark matter in the next 15 years. As a result of this anticipated shift, microbial cultivation will rapidly rise, altering the diversity of microorganisms and underlying lineages.
Roshan Kumar, Utkarsh Sood, Jasvinder Kaur, Shailly Anand, Vipin Gupta, Kishor Sureshbhai Patil, Rup Lal   +6 more
wiley   +1 more source

Bicyclic Boronate β‐Lactamase Inhibitors: The Present Hope against Deadly Bacterial Pathogens

Advanced Therapeutics, Volume 4, Issue 5, May 2021., 2021
This article highlights the therapeutic potential of recently developed bicyclic boronate inhibitors, such as taniborbactam (VNRX‐5133), VNRX‐7145, and QPX‐7728, for restoring the efficacy of β‐lactam antibiotics against multi‐drug resistant bacteria having distinct resistance mechanisms.
Emilio Lence, Concepción González‐Bello   +1 more
wiley   +1 more source

From clinical trials to daily practice: how to adequately administer sulbactam-durlobactam? alone or combined with imipenem? [PDF]

Curr Opin Infect Dis
Purpose of review Sulbactam-durlobactam (SUL-DUR) is a novel β-lactam/β-lactamase inhibitor combination recently approved for carbapenem-resistant Acinetobacter baumannii (CRAB) infections.
Bonazzetti C, Giannella M, Pascale R.
europepmc   +5 more sources

In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates. [PDF]

J Antimicrob Chemother
Abstract Objectives To evaluate the in vitro activity of cefepime in association with a β-lactamase inhibitor (enmetazobactam) or β-lactam enhancer (BLE), zidebactam, against carbapenem-resistant Acinetobacter baumannii (CRAB) strains susceptible or resistant to sulbactam/durlobactam.
Tascini C, Bianco G, Bonomo RA, Gaibani P.   +3 more
europepmc   +6 more sources

Management of extensively drug-resistant <i>Acinetobacter baumannii</i> bacteremia with cefiderocol and sulbactam-durlobactam: a case report. [PDF]

ASM Case Rep
ABSTRACT Background Extensively drug-resistant (XDR) Acinetobacter baumannii presents an urgent threat to public health due to its significant morbidity and mortality, with limited evidence-based treatment options.
Kim EJ, Snyder M, Macaluso K, Sonyey A, Segovia F, Finkel D, Cennimo D, Kim EL.   +7 more
europepmc   +3 more sources

Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical Laboratory

Antibiotics, 2023
The rapid emergence of multi-drug resistant Gram-negative pathogens has driven the introduction of novel β-lactam combination agents (BLCs) to the antibiotic market: ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem ...
Carmella Russo, Romney Humphries
doaj   +1 more source

Successful Treatment of Carbapenem-Resistant Acinetobacter baumannii Meningitis With Sulbactam-Durlobactam. [PDF]

Clin Infect Dis
Abstract Background The treatment of carbapenem-resistant Acinetobacter baumannii/calcoaceticus complex (CRAB) presents significant treatment challenges. Methods We report the case of a 42-year-old woman with CRAB meningitis who ...
Tamma PD, Immel S, Karaba SM, Soto CL, Conzemius R, Gisriel E, Tekle T, Stambaugh H, Johnson E, Tornheim JA, Simner PJ.   +10 more
europepmc   +3 more sources